NCT04099303View on ClinicalTrials.gov

Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .

PHASE1CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

October 27, 2021

Study Completion Date

November 25, 2021

Conditions
DiphtheriaTetanusPertussis
Interventions
BIOLOGICAL

Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed

0.5 mL, Intramuscular Other Name: DTcP

BIOLOGICAL

Diphtheria and Tetanus Combined Vaccine, Adsorbed

2mL, Intramuscular Other Name: DT

BIOLOGICAL

Diphtheria-tetanus-acellular pertussis vaccine

0.5 mL, Intramuscular Other Name: DTaP

BIOLOGICAL

Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine

0.5 mL, Intramuscular Other Name: PENTAXIM

Trial Locations (1)

461500

Changge Center for Disease Control and Prevention, Xuchang

Sponsors
All Listed Sponsors
collaborator

Henan Center for Disease Control and Prevention

OTHER_GOV

lead

CanSino Biologics Inc.

INDUSTRY

NCT04099303 - Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed . | Biotech Hunter | Biotech Hunter